Drugs / CombAct-HIB®
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00362336 | Aug 2006 → May 2008 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CombAct-HIB | “Group 2: CombAct-HIB™ + OPV” NCT00362336 ↗ |
| Route | Intramuscular | “0.5 mL, IM” NCT00362336 ↗ |